{
  "schema": "cl.breast.source-concordance-ledger.v1",
  "moduleVersion": "1.6.21",
  "parentVersion": "1.6.20",
  "referenceDate": "2026-10-28",
  "sourceBasis": [
    "SFRO RecoRad 2025 owner-provided full PDF DOI 10.1016/j.canrad.2025.104767",
    "NICE NG101 official recommendations (2023 amendments)",
    "GEC-ESTRO 2026 APBI full-text Table 7",
    "ASTRO/ASCO/SSO 2025 PMRT source"
  ],
  "primarySourceFingerprint": "4f6a9cd7e077f11b82f3a81cce9ec75956be1d1c0ccc2667fca8a38b785599eb",
  "policy": {
    "notClinicalApproval": true,
    "clinicalEngineUnmodified": true,
    "noAutomaticPrescription": true,
    "radarActivations": 0,
    "countryOverrides": 0,
    "dimensions": [
      "source_location",
      "source_semantics",
      "software_behavior",
      "clinical_scope",
      "jurisdiction",
      "unresolved_concordance"
    ]
  },
  "claims": [
    {
      "claimId": "eu-bcs-rt",
      "title": "RT after breast-conserving surgery",
      "candidateRuleIds": [
        "cl.breast.rt.indication.bcs.v1"
      ],
      "primarySourceIds": [
        "sfro-2025",
        "nice-ng101"
      ],
      "locatedStatementIds": [
        "src.sfro2025.abstract.bcs",
        "src.nice.ng101.1.13.7",
        "src.sfro2025.full.bcs-omission"
      ],
      "sourceConcordance": "source-concordant-default; incomplete universal rule",
      "sourceSummary": "SFRO 2025 §2.1.1.1 and Table 5: WBI after BCS is standard; omission discussion requires a narrowly selected group >70 and endocrine/shared decision. NICE NG101 §1.13.7 considers omission from 65 under distinct UK conditions.",
      "implementationObservation": "Current default is recommended. Separate review-only French exception exists; jurisdiction and unencoded special situations remain open.",
      "humanOnlyDecision": "Clinical-signoff of country-specific omission scope, male/TP53 and unusual chronology; documented exceptions must not become automatic no-RT.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "fr-boost-age",
      "title": "Boost indication in younger patients",
      "candidateRuleIds": [
        "cl.breast.rt.boost-under50.v1"
      ],
      "primarySourceIds": [
        "sfro-2025"
      ],
      "locatedStatementIds": [
        "src.sfro2025.abstract.boost",
        "src.eviq3650.v6.boost",
        "src.sfro2025.full.boost-eligibility",
        "src.sfro2025.full.boost-schedules"
      ],
      "sourceConcordance": "partial-source-concordance",
      "sourceSummary": "SFRO 2025 §3.2.1 and Table 5: boost systematic below age 50; ages 50–60 discussed with high-risk factors; >60 for selected high-risk cases.",
      "implementationObservation": "Core emits consider for many factors but may not distinguish strength of source language by age. Numeric boost references remain separate.",
      "humanOnlyDecision": "Exact boost indication strength across age boundaries, high-risk features and prior treatment.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "eu-wbi-exact-dose",
      "title": "Exact WBI 40.05 Gy/15",
      "candidateRuleIds": [
        "cl.breast.rt.wbi-40-15.v1"
      ],
      "primarySourceIds": [
        "estro-acrop-breast-2022",
        "sfro-2025"
      ],
      "locatedStatementIds": [
        "src.estro2022.abstract.moderate-wbi",
        "src.sfro2025.abstract.hypo",
        "src.sfro2025.full.wbi-schedules",
        "src.sfro2025.full.wbi-table-numerical-variance"
      ],
      "sourceConcordance": "source-concordant-number; provenance ambiguity",
      "sourceSummary": "SFRO 2025 §3.1 explicitly lists 40.05 Gy/15; Table 5 renders 40.0 Gy/15. Both statements must be preserved.",
      "implementationObservation": "Code displays 40.05 Gy/15 for non-nodal WBI, sourced through a non-European eviQ reference; the French full text now supports 40.05/15 but reference lineage should be corrected.",
      "humanOnlyDecision": "Confirm exact local recommended schedule and source edition; do not silently round or assert identity.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "eu-rni-dose",
      "title": "Regional nodal RT dose and volume",
      "candidateRuleIds": [
        "cl.breast.rt.wbi-regional-40-15.v1"
      ],
      "primarySourceIds": [
        "estro-acrop-breast-2022",
        "nice-ng101",
        "sfro-2025"
      ],
      "locatedStatementIds": [
        "src.estro2022.abstract.moderate-regional",
        "src.nice.ng101.1.13.16",
        "src.sfro2025.abstract.regional-nodal",
        "src.sfro2025.full.regional-dose",
        "src.sfro2025.full.axillary-criteria",
        "src.sfro2025.full.imn-risk"
      ],
      "sourceConcordance": "source-concordant-reference; volume selection incomplete",
      "sourceSummary": "SFRO 2025 §3.4/Table 5 includes 40.05 Gy/15 for regional nodes; NICE NG101 §1.13.16 recommends 40 Gy/15. Axillary/SCV/IMN coverage requires separate criteria (SFRO Tables 2–3).",
      "implementationObservation": "Code references NICE 40/15; node count can trigger regional radiation without complete nodal stations selection.",
      "humanOnlyDecision": "Review nodal levels, axillary management, IMN risks and dose/OAR by patient.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "eu-5fx-breast",
      "title": "Five-fraction non-nodal breast RT",
      "candidateRuleIds": [
        "cl.breast.rt.wbi-26-5.v1"
      ],
      "primarySourceIds": [
        "estro-acrop-breast-2022",
        "nice-ng101",
        "sfro-2025"
      ],
      "locatedStatementIds": [
        "src.estro2022.abstract.five-fraction",
        "src.nice.ng101.1.13.13",
        "src.sfro2025.abstract.ultra-26",
        "src.sfro2025.full.five-fraction-conditions"
      ],
      "sourceConcordance": "conditional-source-concordance",
      "sourceSummary": "SFRO 2025 §3.1 and Table 5 offer 26 Gy/5 WBI without boost or regional nodal RT; NICE recommends 26 Gy/5 non-nodal within UK recommendations.",
      "implementationObservation": "Code generally withholds 26/5 when boost or RNI is identified; unknown boost context can remain an applicability issue.",
      "humanOnlyDecision": "Validate actual boost/nodal indication and fractionation/OAR; do not universally default to five fractions.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "uk-pbi",
      "title": "PBI option and technique",
      "candidateRuleIds": [
        "cl.breast.rt.pbi-30-5.v1"
      ],
      "primarySourceIds": [
        "nice-ng101",
        "estro-acrop-breast-2022"
      ],
      "locatedStatementIds": [
        "src.nice.ng101.1.13.4",
        "src.nice.ng101.1.13.6",
        "src.sfro2025.full.pbi-eligibility",
        "src.sfro2025.full.external-pbi-schedules"
      ],
      "sourceConcordance": "cross-jurisdictional-conditional",
      "sourceSummary": "NICE NG101 §§1.13.4–1.13.6 describes selected PBI and external-beam technique in UK. SFRO 2025 PBI criteria differ from GEC-ESTRO 2026 expanded selection.",
      "implementationObservation": "External-beam PBI 30/5 is cited to ASTRO/eviQ; NICE source does not uniquely validate that exact 30/5 regimen.",
      "humanOnlyDecision": "Verify eligibility and the exact treatment technique/dose source by jurisdiction.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "eu-dcis-rt",
      "title": "DCIS RT and numerical WBI",
      "candidateRuleIds": [
        "cl.breast.rt.dcis-40-15.v1"
      ],
      "primarySourceIds": [
        "sfro-2025",
        "nice-ng101"
      ],
      "locatedStatementIds": [
        "src.nice.ng101.1.13.9",
        "src.sfro2025.full.dcis-treatment"
      ],
      "sourceConcordance": "source-concordant-standard; exceptions incomplete",
      "sourceSummary": "SFRO 2025 §2.2/Table 5: RT is standard after BCS for DCIS; omission in low-risk DCIS is currently reserved for trials in this source. Selected DCIS APBI is addressed differently by GEC-ESTRO 2026.",
      "implementationObservation": "DCIS WBI numerical reference is available; no patient-specific omission. Source applicability must not treat GEC APBI as evidence for DCIS omission.",
      "humanOnlyDecision": "DCIS grade/size/margins, boost risk and trial-only omission pathway.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "fr-postneo",
      "title": "Postmastectomy RT after neoadjuvant therapy",
      "candidateRuleIds": [
        "cl.breast.rt.pmrt-40-15.v1"
      ],
      "primarySourceIds": [
        "sfro-2025",
        "nice-ng101"
      ],
      "locatedStatementIds": [
        "src.sfro2025.abstract.neoadjuvant-pmrt",
        "src.nice.ng101.1.13.26-29",
        "src.sfro2025.full.postneo-pmrt",
        "src.sfro2025.full.chest-wall-dose"
      ],
      "sourceConcordance": "conditional-source-concordance",
      "sourceSummary": "SFRO 2025 §2.1.5 and Table 5 distinguish ypN+ from initially cN+ converted to ypN0 and cite B-51; ASTRO/ASCO/SSO 2025 gives conditional recommendation for selected cT1–3N1/ypN0.",
      "implementationObservation": "Code considers initial and residual nodes; RT phases are teaching references and do not resolve every response/subtype exception.",
      "humanOnlyDecision": "Clinical scenario-by-scenario comparison of subtype, initial burden, pathologic response and endpoint.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "eu-brachy-option",
      "title": "Brachytherapy as partial-breast alternative",
      "candidateRuleIds": [
        "cl.breast.brachy.pbi-hdr.v1"
      ],
      "primarySourceIds": [
        "gec-estro-apbi-2023",
        "nice-ng101"
      ],
      "locatedStatementIds": [
        "src.nice.ng101.1.13.6",
        "src.sfro2025.full.brachy-apbi-schedules",
        "src.sfro2025.full.boost-brachy"
      ],
      "sourceConcordance": "source-linked-dose; eligibility edition difference",
      "sourceSummary": "SFRO 2025 §3.3.2 lists HDR PBI 32 Gy/8 or 30.1 Gy/7; GEC-ESTRO 2026 Table 7 updates APBI eligibility and permits selected DCIS while excluding pNx, TNBC, known BRCA mutation and neoadjuvant chemotherapy.",
      "implementationObservation": "Code has independent GEC eligibility assessor and HDR schedule references; APBI selection is not a finalized prescription.",
      "humanOnlyDecision": "Resolve exact age=40 wording difference in 2026 source (Table 7 >40 versus prose ≥40); technique-specific contouring and constraints.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    },
    {
      "claimId": "fr-rt-systemic-chronology",
      "title": "RT and systemic sequence",
      "candidateRuleIds": [
        "cl.breast.rt.indication.bcs.v1"
      ],
      "primarySourceIds": [
        "sfro-2025"
      ],
      "locatedStatementIds": [
        "src.sfro2025.abstract.systemic-sequencing",
        "src.sfro2025.full.systemic-timing"
      ],
      "sourceConcordance": "source-concordant-principle; regimen-level incomplete",
      "sourceSummary": "SFRO 2025 §8.1–8.2: adjuvant chemotherapy usually precedes RT; endocrine timing may vary, and selected targeted/immunotherapies have agent-specific cautions.",
      "implementationObservation": "Current histories and drug references are separate but no complete all-agents temporal interaction engine is claimed.",
      "humanOnlyDecision": "Verify actual medicine exposure, hold/continue interactions, toxicity and dose modifications from current SmPC/consensus.",
      "clinicalApproval": "NOT_APPROVED",
      "radarDependencyActive": false
    }
  ],
  "candidateRules": [
    {
      "ruleId": "cl.breast.rt.indication.bcs.v1",
      "domain": "External-beam RT",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "wb?.status==='recommended'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "sfro-2025",
        "ago-early-2026"
      ],
      "preciseSourceStatementIds": [
        "src.sfro2025.abstract.bcs",
        "src.nice.ng101.1.13.7",
        "src.sfro2025.full.bcs-omission",
        "src.sfro2025.full.systemic-timing",
        "src.sfro2025.full.tp53-reirradiation"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.rt.boost-under50.v1",
      "domain": "Boost",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "const boostIndicated=",
      "anchorVerified": true,
      "candidateSourceIds": [
        "sfro-2025"
      ],
      "preciseSourceStatementIds": [
        "src.eviq3650.v6.prescription",
        "src.sfro2025.abstract.boost",
        "src.sfro2025.full.boost-eligibility",
        "src.sfro2025.full.boost-schedules"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.rt.wbi-40-15.v1",
      "domain": "RT fractionation",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "schedule('wbi-40-15'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "eviq-wbi",
        "sfro-2025"
      ],
      "preciseSourceStatementIds": [
        "src.eviq3650.v6.prescription",
        "src.estro2022.abstract.moderate-wbi",
        "src.sfro2025.full.wbi-schedules",
        "src.sfro2025.full.wbi-table-numerical-variance",
        "src.sfro2025.full.oar-dose-constraints"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.rt.wbi-regional-40-15.v1",
      "domain": "RT nodal targets",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "schedule('wbi-rni-40-15'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "nice-ng101",
        "estro-2016",
        "eviq-wbi"
      ],
      "preciseSourceStatementIds": [
        "src.nice.ng101.1.13.16",
        "src.nice.ng101.1.13.19",
        "src.nice.ng101.1.13.21",
        "src.nice.ng101.1.13.22",
        "src.nice.ng101.1.13.23",
        "src.estro2022.abstract.moderate-regional",
        "src.sfro2025.abstract.regional-nodal",
        "src.sfro2025.full.regional-dose",
        "src.sfro2025.full.axillary-criteria",
        "src.sfro2025.full.imn-risk",
        "src.sfro2025.full.oar-dose-constraints",
        "src.sfro2025.full.contouring-interfaces"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.rt.wbi-26-5.v1",
      "domain": "RT fractionation",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "schedule('wbi-26-5'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "nice-ng101",
        "fastforward-2020"
      ],
      "preciseSourceStatementIds": [
        "src.nice.ng101.1.13.13",
        "src.estro2022.abstract.five-fraction",
        "src.sfro2025.abstract.ultra-26",
        "src.sfro2025.full.five-fraction-conditions"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.rt.pbi-30-5.v1",
      "domain": "Partial breast",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "schedule('pbi-30-5'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "astro-pbi-2024",
        "eviq-pbi"
      ],
      "preciseSourceStatementIds": [
        "src.nice.ng101.1.13.4",
        "src.sfro2025.full.pbi-eligibility",
        "src.sfro2025.full.external-pbi-schedules"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.rt.dcis-40-15.v1",
      "domain": "DCIS RT",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "schedule('dcis-wbi-40-15'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "eviq-dcis",
        "ago-early-2026"
      ],
      "preciseSourceStatementIds": [
        "src.nice.ng101.1.13.9",
        "src.sfro2025.full.dcis-treatment"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.rt.pmrt-40-15.v1",
      "domain": "PMRT",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "schedule('pmrt-rni-40-15'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "nice-ng101",
        "astro-pmrt-2025"
      ],
      "preciseSourceStatementIds": [
        "src.nice.ng101.1.13.16",
        "src.nice.ng101.1.13.26-29",
        "src.estro2022.abstract.moderate-regional",
        "src.sfro2025.abstract.neoadjuvant-pmrt",
        "src.sfro2025.full.chest-wall-dose",
        "src.sfro2025.full.postneo-pmrt"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.endocrine.tamoxifen.v1",
      "domain": "Endocrine",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'tamoxifen-20-daily'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "tamoxifen-smpc"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.endocrine.letrozole.v1",
      "domain": "Endocrine",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'letrozole-2.5-daily'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "letrozole-smpc"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.endocrine.anastrozole.v1",
      "domain": "Endocrine",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'anastrozole-1-daily'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "anastrozole-smpc"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.targeted.abemaciclib.v1",
      "domain": "Targeted",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'abemaciclib-adjuvant-2y'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "verzenios-ema",
        "asco-cdk46-2024"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.targeted.ribociclib.v1",
      "domain": "Targeted",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'ribociclib-adjuvant-3y'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "kisqali-ema",
        "asco-cdk46-2024"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.targeted.tdm1.v1",
      "domain": "Targeted",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'tdm1-adjuvant-14'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "kadcyla-ema"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.chemo.ac-taxane.v1",
      "domain": "Chemotherapy",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'ddac-then-weekly-paclitaxel'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "eviq-ddac-4102",
        "eviq-paclitaxel-4103",
        "eviq-ddac-paclitaxel-4010"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.chemo.tc-alternative.v1",
      "domain": "Chemotherapy",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "id:'tc-adjuvant-alt'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "eviq-tc-24"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.chemo.genomic-risk.v1",
      "domain": "Chemotherapy",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "genomicRule?",
      "anchorVerified": true,
      "candidateSourceIds": [
        "asco-tailorx-2019",
        "asco-biomarkers-2022",
        "nci-tailorx-2018"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.immuno.adjuvant-continuation.v1",
      "domain": "Immunotherapy",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "neoPembrolizumab",
      "anchorVerified": true,
      "candidateSourceIds": [
        "keytruda-ema",
        "eviq-tnbc-perioperative"
      ],
      "preciseSourceStatementIds": [],
      "sourceReferenceLevel": "source-edition-only",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    },
    {
      "ruleId": "cl.breast.brachy.pbi-hdr.v1",
      "domain": "Brachytherapy",
      "implementationAsset": "assets/breast-decision-bundle.js",
      "implementationAnchor": "schedule('hdr-multicatheter-pbi-32-8'",
      "anchorVerified": true,
      "candidateSourceIds": [
        "gec-estro-apbi-2023",
        "abs-brachy-2017",
        "astro-pbi-technique-2024",
        "gec-estro-apbi-2026"
      ],
      "preciseSourceStatementIds": [
        "src.sfro2025.full.boost-brachy",
        "src.sfro2025.full.pbi-eligibility",
        "src.sfro2025.full.brachy-apbi-schedules",
        "src.gecestro2026.apbi-dcis-selection"
      ],
      "sourceReferenceLevel": "source-located",
      "clinicalSemanticReview": "NOT_APPROVED",
      "countryApplicability": "NOT_APPROVED",
      "radarActive": false,
      "expertFocus": "Resolve only remaining applicability, conflicts, treatment tradeoffs, and local adoption after automated checks"
    }
  ],
  "sourceStatementCount": 48,
  "reviewQuestionCount": 12,
  "internalSourceAmbiguities": [
    {
      "id": "sfro-dose-text-v-table",
      "source": "sfro-2025",
      "location": "§3.1 vs Table 5",
      "observation": "40.05 Gy/15 detailed section versus 40.0 Gy/15 summary table",
      "resolution": "Retain both exact transcriptions and the source passages; ask editor only if clinically material to precision policy"
    },
    {
      "id": "sfro-pmrt-pt3",
      "source": "sfro-2025",
      "location": "§2.1.2 vs Table 5",
      "observation": "pT3N0 benefits described as debatable whereas Table 5 includes T3 under indicated PMRT",
      "resolution": "Do not reduce all pT3N0 cases to a categorical automatic recommendation"
    },
    {
      "id": "gecestro-age-40",
      "source": "gec-estro-apbi-2026",
      "location": "Table 7 vs article prose",
      "observation": "Table 7 >40 and high-risk ≤40, while prose also uses at least 40",
      "resolution": "Treat exactly 40 as review-needed until authors or authoritative correction reconcile wording"
    },
    {
      "id": "sfro-axillary-itc-table",
      "source": "sfro-2025",
      "location": "Table 2",
      "observation": "Isolated-tumour-cell cell-size label appears inconsistent with the adjacent micrometastatic range",
      "resolution": "Use pathological classification definitions rather than copying the conflicting table typography"
    },
    {
      "id": "sfro-regional-levels-print",
      "source": "sfro-2025",
      "location": "§2.1.4.2",
      "observation": "One sentence lists lumbar L1–4 among breast regional nodes, likely editorial terminology",
      "resolution": "Do not use that phrase as an anatomical contouring instruction without authoritative cross-check"
    }
  ],
  "reviewerWorkOnly": [
    "Clinical exceptions not specified in sources",
    "Benefit–risk judgment for special circumstances",
    "Institutional implementation, local dose constraints",
    "Formal author/source interpretation of internal wording ambiguity",
    "Outcomes from real-case concordance reviews"
  ],
  "notVerified": [
    "Completeness of all European and national breast guidelines",
    "Full original ESMO recommendation-level mapping",
    "Formal authorization to activate Radar clinical dependencies",
    "Prospective outcome validation"
  ]
}
